Imatinib: Transforming Cancer Treatment with Targeted Therapy
Imatinib is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL fusion protein, an abnormal enzyme produced by a genetic mutation responsible for chronic myeloid leukemia (CML) and some forms of acute lymphoblastic leukemia (ALL).
